Anesthesiology Case Reports

Cardiology Case Reports

Dentistry Case Reports

Diabetology Case Reports

Gastroenterology Case Reports

Otolaryngology Case Reports

Improving the Efficacy of Cisplatin in Colon Cancer HT– 29 Cells via Combination Therapy withSelenium


Amend K

Physicians Assistant Program, University of Saint Francis, Fort Wayne, IN.

Correspondence to Author:  Amend K


In general, cis-platinum is ineffective in treating slow-growing colon cancer. A seleno-enzyme that neutralises reactive oxygen species is glutathione peroxidase (ROS). High ROS concentrations may affect the efficacy of cisplatinum, according to research. In HT-29 colon cancer cells, the impact of selenite supplementation during cis-platinum treatment was investigated. Agarose culture enables cells to form colonies, grow in three dimensions, and independently analyse mitosis, cell viability, and ROS production. Single cells were cultivated for seven days while suspended in agarose. At day 0, cultures were either left untreated with selenite or were pretreated with it. Cultures were either given cis-platinum alone or in combination with selenite on day 4. Cell viability and mitotic activity were assessed after 7 days. ROS degradation was measured using a glutathione peroxidase test.activity. Little dosages of selenite had no impact on mitosis or cell survival. More ROS breakdown and improved cis-platinum efficacy were seen in cultures that were treated with selenite and cis-platinum. If colonies are already present, cisplatinum alone proved less efficient than the combination of cis-platinum and selenite. Moreover, cells treated with the cisplatinum and selenite combination showed enhanced ROS breakdown, indicating a connection between ROS levels and cisplatinum efficacy.


Amend K. Improving the Efficacy of Cisplatin in Colon Cancer HT– 29 Cells via Combination Therapy withSelenium. Clinical Imaging and Case Reports 2023.

Journal Info

  • Journal Name: Clinical Imaging and Case Reports
  • Impact Factor: 2.709**
  • ISSN: 2770-9205
  • DOI: 10.52338/cicaserep
  • Short Name: CICASEREP
  • Acceptance rate: 55%
  • Volume: 6 (2024)
  • Submission to acceptance: 25 days
  • Acceptance to publication: 10 days


  • Crossref indexed journal
  • Publons indexed journal
  • Pubmed-indexed journal
  • International Scientific Indexing (ISI)-indexed journal
  • Eurasian Scientific Journal Index (ESJI) index journal
  • Semantic Scholar indexed journal
  • Cosmos indexed journal


  • International Reach
  • Peer Review
  • Rapid Publication
  • Open Access
  • High Visibility